##EasyReadMore##

Wednesday, November 10, 2010

11/10 PR Newswire: Health

     
    PR Newswire: Health    
   
Nuevo estudio publicado: los Lactobacillus reuteri Prodentis resultan eficaces para el tratamiento de la periodontitis
November 10, 2010 at 5:00 PM
 

http://www.newscom.com/cgi-bin/prnc/20101110/418565ESTOCOLMO, 10 de noviembre de 2010 /PRNewswire/ -- Un nuevo estudio muestra que los L. reuteri Prodentis actúan de forma sinérgica con el tratamiento estándar (decapado y alisado radicular, SRP, por sus siglas en inglés) para reducir significativamente la profundidad de sondaje d


Media Files
418565
   
   
Novo estudo publicado: Lactobacillus reuteri Prodentis eficaz no tratamento de periodontite
November 10, 2010 at 5:00 PM
 

http://www.newscom.com/cgi-bin/prnc/20101110/418565ESTOCOLMO, 10 de novembro de 2010 /PRNewswire/ -- O estudo mostra que o L. reuteri Prodentis age sinergisticamente com o tratamento padrão (raspagem tradicional e regularização da raiz, SRP) reduzindo significativamente a profundidade da cavidade para sondagem (PPD) e nível cl


Media Files
418565
   
   
New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis
November 10, 2010 at 5:00 PM
 

http://www.newscom.com/cgi-bin/prnc/20101110/418565 STOCKHOLM, November 10, 2010 /PRNewswire-FirstCall/ -- The study shows that L. reuteri Prodentis acts synergistically with standard treatment (scaling and root plaining, SRP) to significantly reduce probing pocket depth (PPD) and clinical attachment level (CAL) which are the two most important p


Media Files
418565
   
   
Silence Therapeutics' Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
November 10, 2010 at 4:00 PM
 
LONDON, Nov. 10, 2010 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces positive research findings demonstrating the ability of the Company's lead RNA interference (RNAi) drug candidate, Atu027, to prevent the formation of pulmonary metastasis in various anim
   
   
Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics
November 10, 2010 at 3:00 PM
 
BASEL, Switzerland and WILMINGTON, Del., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Syngenta and DuPont today announced that Syngenta has assumed full ownership of GreenLeaf Genetics, LLC, effective November 8, 2010. The transaction dissolves a joint venture between Syngenta Seeds, Inc. and DuPont busi
   
   
Tianyin to Attend Brean Murray, Carret & Co. 2010 China Growth Conference on November 17 - 18, 2010
November 10, 2010 at 2:00 PM
 
CHENGDU, China, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals will attend Brean Murr
   
   
Press Material from Cipla available on thenewsmarket.com: Cipla Gets APVMA Approval to Introduce Generic Omeprazole in Australia for Treating Equine Ulcers
November 10, 2010 at 1:30 PM
 
NEW YORK, Nov. 9, 2010 /PRNewswire/ -- See Still Image from Cipla at: http://www.thenewsmarket.com/CustomLink/CustomLinks.aspx?GUID=7d84d552-15c1-4161-bc08-40a209cf6c99 Cipla, one of the world's leading generic pharmaceutical companies is the first from India to get The Australian Pesticides and Ve
   
   
Entrust President and CEO Bill Conner Addresses Global Dignitaries During INTERPOL 79th General Assembly
November 10, 2010 at 11:35 AM
 

http://photos.prnewswire.com/prnc/20060720/NYTH074LOGODALLAS, Nov. 9, 2010 /PRNewswire/ -- Entrust, Inc. President and CEO Bill Conner addressed global security and law enforcement leaders during INTERPOL's 79th General Assembly in Doha, Qatar, Monday. With many dignitaries, officials and ministers in attendance, Conner explained the current identity f


Media Files
NYTH074LOGO
   
   
Global Leaders Combine Forces to Provide Identity Security Documents for INTERPOL
November 10, 2010 at 11:30 AM
 

http://photos.prnewswire.com/prnc/20060720/NYTH074LOGODOHA, Qatar, DALLAS and KIEV, Ukraine, Nov. 9, 2010 /PRNewswire/ -- ENTRUST, the U.S. company that provides identity-based security solutions for nine of the top 10 global e-governments, partnered with EDAPS, the Ukrainian consortium of high-tech companies, to provide INTERPOL with unprecedented, hi


Media Files
NYTH074LOGO
   
   
Luoxin Pharma Announces 2010 Third Quarterly Results
November 10, 2010 at 11:15 AM
 
HONG KONG, Nov. 9, 2010 /PRNewswire-Asia/ -- Shandong Luoxin Pharmacy Stock Co., Ltd. ("Luoxin Pharma" or the "Company", stock code: 8058), one of the leading PRC pharmaceutical enterprises, announced its results for the nine months ended 30 September 2010 ("the period under review") today, reco
   
   
Mylan Announces Pricing of Senior Notes
November 10, 2010 at 10:12 AM
 
PITTSBURGH, Nov. 9, 2010 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced the pricing in the private placement of senior notes announced earlier today. Mylan priced $800 million aggregate principal amount of 6.0% Senior Notes due 2018 at an issue price of 98.450%.  Mylan
   
   
New Inspired-Giving Catalog Offers Gifts That Give a Hand-Up to the Poor This Holiday Season
November 10, 2010 at 10:09 AM
 
INDEPENDENCE, Mo., Nov. 9, 2010 /PRNewswire/ -- Outreach International, a humanitarian organization based in Greater Kansas City, Missouri, announces its 2010 holiday shopping solution. For the person who has everything, the new Sustainable Gifts Catalog is filled with meaningful gifts that make a l
   
   
American Oriental Bioengineering Introduces Kangfuling Suppository
November 10, 2010 at 9:53 AM
 
NEW YORK, Nov. 9, 2010 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), (the "Company" or "AOB"), a pharmaceutical company dedicated to improving healthcare through the development, manufacture and commercialization of a broad range of prescription and over-the-coun
   
   
Expertos Llaman a Abordar Riesgo de Parto Prematuro al Inicio del Embarazo
November 10, 2010 at 9:17 AM
 
WHITE PLAINS, Nueva York, 9 de noviembre del 2010 /PRNewswire-HISPANIC PR WIRE/ -- Doctores y pacientes deben conversar sobre el riesgo que presenta una embarazada de parto prematuro en la décimo segunda semana del embarazo, según un comentario publicado en la edición de noviembre de
   
   
FDA: Majority of Drug and Biological Product Makers Meeting Postmarketing Requirements and Commitments
November 10, 2010 at 8:59 AM
 

http://photos.prnewswire.com/prnc/20090824/FDALOGO2nd annual report based on more than 1,500 postmarketing studies, clinical trials SILVER SPRING, Md., Nov. 9, 2010 /PRNewswire-USNewswire/ -- Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in


Media Files
FDALOGO
   
     
 
This email was sent to xupan0000@gmail.com.
Delivered by Feed My Inbox
230 Franklin Road Suite 814 Franklin, TN 37064
Create Account
Unsubscribe Here Feed My Inbox
 
     

No comments:

Not What You Were Looking For? Try a new Google Web Search